SUMMIT, N.J., Dec. 7, 2010 (GLOBE NEWSWIRE) -- Protalex, Inc. (OTCBB:PRTX), a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases, announced that a one-for-five reverse stock split of its shares of common stock and the authorization of a “blank-check” class of preferred stock will become effective as of 9:00 a.m. eastern time tomorrow, December 8, 2010. Trading of the Company’s common stock on the OTC Bulletin Board on a split-adjusted basis will begin at the open of trading tomorrow under the ticker symbol “PRTXD.” After 20 trading days, the ticker symbol will revert to “PRTX.”
